Partners

BCN HEALTH presents three communications in the congress ISPOR Europe based on retrospective claims database analysis for the identification of patients

The objectives of the study were to describe patient characteristics, calculate hospital incidence and mortality associated with Alzheimer's disease in Spain, and assess direct medical costs at hospital level from the perspective of the National Health System

bcn health
Healthcare

BCN HEALTH presents the poster "Hospital incidence, mortality and costs of Alzheimer's disease in Spain: a retrospective multicenter study" on a retrospective study that included records of Alzheimer's disease patients admitted to hospitals in Spain between 2011 and 2016. The objectives of the study were to describe patient characteristics, calculate hospital incidence and mortality associated with Alzheimer's disease in Spain, and assess direct medical costs at hospital level from the perspective of the National Health System. This study included 7,894 patients, 62% of whom were women with an average age of 80.4 years. This study provides evidence of the growing burden that Alzheimer's disease represents for hospital settings, both in terms of number of hospitalisations and medical costs, highlighting the importance of early detection and optimisation of care.

The poster "Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain" shows the results of the analysis of 23,315 records of patients with intrahepatic cholangiocarcinoma in Spain extracted from a database containing records from 192 private and 313 public centres from 1997 to 2018. The aim of this study was to assess the hospital incidence, healthcare resource use and direct medical cost of patients with intrahepatic cholangiocarcinoma in Spain between 2000 and 2018. 55.5% of patients under study were men with a mean age of 73 years. The results of the study highlight that the incidence of intrahepatic cholangiocarcinoma in Spain has increased in recent years and that although medical costs per patient stabilised after 2008, total costs are expected to increase if the incidence continues to rise.

Finally, the poster "Epidemiology and management of parathyroid gland disorders in Spain over 15 years: a retrospective multicenter analysis" summarises the results obtained after analysing data on patients diagnosed with parathyroid gland disorders in Spain between 2003 and 2017. The data were obtained from a database of the Ministry of Health. This study aimed to obtain new epidemiological data and characteristics of patients admitted for parathyroid gland disorders in Spanish hospitals, as well as to assess the management and direct medical costs of the disease. The study included 12,903 patients, 74.7% of whom were women. Of the total admissions, 90.23% were related to hyperparathyroidism. This study concludes that data describing the epidemiology and burden of parathyroid gland disorders are scarce, making it difficult to formulate clinical guidelines based on real-world data. The development and revision of management guidelines focusing on patients with hypoparathyroidism would be necessary, taking into account the large percentage of patients requiring urgent care.